121 related articles for article (PubMed ID: 17725424)
1. Drug resistance in plasma and breast milk after single-dose nevirapine in subtype C HIV type 1: population and clonal sequence analysis.
Kassaye S; Lee E; Kantor R; Johnston E; Winters M; Zijenah L; Mateta P; Katzenstein D
AIDS Res Hum Retroviruses; 2007 Aug; 23(8):1055-61. PubMed ID: 17725424
[TBL] [Abstract][Full Text] [Related]
2. Emergence of NNRTI drug resistance mutations after single-dose nevirapine exposure in HIV type 1 subtype C-infected infants in India.
Kurle SN; Gangakhedkar RR; Sen S; Hayatnagarkar SS; Tripathy SP; Paranjape RS
AIDS Res Hum Retroviruses; 2007 May; 23(5):682-5. PubMed ID: 17530993
[TBL] [Abstract][Full Text] [Related]
3. Genetic linkage of nevirapine resistance mutations in HIV type 1 seven days after single-dose nevirapine.
Jones D; Parkin N; Hudelson SE; Guay LA; Musoke P; Mmiro F; Jackson JB; Eshleman SH
AIDS Res Hum Retroviruses; 2005 Apr; 21(4):319-24. PubMed ID: 15943576
[TBL] [Abstract][Full Text] [Related]
4. Characterization of nevirapine (NVP) resistance mutations and HIV type 1 subtype in women from Abidjan (Côte d'Ivoire) after NVP single-dose prophylaxis of HIV type 1 mother-to-child transmission.
Toni TD; Masquelier B; Lazaro E; Dore-Mbami M; Ba-Gomis FO; Téa-Diop Y; Kouakou K; Diby J; Sia E; Soppi S; Essien S; Schrive MH; Pinson P; Chenal H; Fleury HJ
AIDS Res Hum Retroviruses; 2005 Dec; 21(12):1031-4. PubMed ID: 16379606
[TBL] [Abstract][Full Text] [Related]
5. Minor drug-resistant HIV type-1 variants in breast milk and plasma of HIV type-1-infected Ugandan women after nevirapine single-dose prophylaxis.
Pilger D; Hauser A; Kuecherer C; Mugenyi K; Kabasinguzi R; Somogyi S; Harms G; Kunz A
Antivir Ther; 2011; 16(1):109-13. PubMed ID: 21311114
[TBL] [Abstract][Full Text] [Related]
6. Breast-milk shedding of drug-resistant HIV-1 subtype C in women exposed to single-dose nevirapine.
Lee EJ; Kantor R; Zijenah L; Sheldon W; Emel L; Mateta P; Johnston E; Wells J; Shetty AK; Coovadia H; Maldonado Y; Jones SA; Mofenson LM; Contag CH; Bassett M; Katzenstein DA;
J Infect Dis; 2005 Oct; 192(7):1260-4. PubMed ID: 16136470
[TBL] [Abstract][Full Text] [Related]
7. A post-partum single-dose TDF/FTC tail does not prevent the selection of NNRTI resistance in women receiving pre-partum ZDV and intrapartum single-dose nevirapine to prevent mother-to- child HIV-1 transmission.
Samuel R; Paredes R; Parboosing R; Moodley P; Singh L; Naidoo A; Gordon M
J Med Virol; 2015 Oct; 87(10):1662-7. PubMed ID: 25940687
[TBL] [Abstract][Full Text] [Related]
8. HIV type 1 pol gene diversity and archived nevirapine resistance mutation in pregnant women in Rwanda.
Servais J; Lambert C; Karita E; Vanhove D; Fischer A; Baurith T; Schmit JC; Schneider F; Hemmer R; Arendt V
AIDS Res Hum Retroviruses; 2004 Mar; 20(3):279-83. PubMed ID: 15117451
[TBL] [Abstract][Full Text] [Related]
9. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.
Bannister WP; Ruiz L; Cozzi-Lepri A; Mocroft A; Kirk O; Staszewski S; Loveday C; Karlsson A; Monforte Ad; Clotet B; Lundgren JD;
AIDS; 2008 Jan; 22(3):367-76. PubMed ID: 18195563
[TBL] [Abstract][Full Text] [Related]
10. Intrapartum tenofovir and emtricitabine reduces low-concentration drug resistance selected by single-dose nevirapine for perinatal HIV prevention.
Chi BH; Ellis GM; Chintu N; Cantrell RA; Sinkala M; Aldrovandi GM; Warrier R; Mbewe F; Nakamura K; Stringer EM; Frenkel LM; Stringer JS
AIDS Res Hum Retroviruses; 2009 Nov; 25(11):1099-106. PubMed ID: 19886836
[TBL] [Abstract][Full Text] [Related]
11. Comparison of nevirapine (NVP) resistance in Ugandan women 7 days vs. 6-8 weeks after single-dose nvp prophylaxis: HIVNET 012.
Eshleman SH; Guay LA; Mwatha A; Cunningham SP; Brown ER; Musoke P; Mmiro F; Jackson JB
AIDS Res Hum Retroviruses; 2004 Jun; 20(6):595-9. PubMed ID: 15242535
[TBL] [Abstract][Full Text] [Related]
12. Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated.
Johnson JA; Li JF; Morris L; Martinson N; Gray G; McIntyre J; Heneine W
J Infect Dis; 2005 Jul; 192(1):16-23. PubMed ID: 15942889
[TBL] [Abstract][Full Text] [Related]
13. Slower clearance of nevirapine resistant virus in infants failing extended nevirapine prophylaxis for prevention of mother-to-child HIV transmission.
Persaud D; Bedri A; Ziemniak C; Moorthy A; Gudetta B; Abashawl A; Mengistu Y; Omer SB; Isehak A; Kumbi S; Adamu R; Lulseged S; Ashworth R; Hassen E; Ruff A;
AIDS Res Hum Retroviruses; 2011 Aug; 27(8):823-9. PubMed ID: 21241214
[TBL] [Abstract][Full Text] [Related]
14. Clonal amplification and maternal-infant transmission of nevirapine-resistant HIV-1 variants in breast milk following single-dose nevirapine prophylaxis.
Permar SR; Salazar MG; Gao F; Cai F; Learn GH; Kalilani L; Hahn BH; Shaw GM; Salazar-Gonzalez JF
Retrovirology; 2013 Aug; 10():88. PubMed ID: 23941304
[TBL] [Abstract][Full Text] [Related]
15. Variability in the plasma concentration of efavirenz and nevirapine is associated with genotypic resistance after treatment interruption.
Darwich L; Esteve A; Ruiz L; Bellido R; Clotet B; Martinez-Picado J
Antivir Ther; 2008; 13(7):945-51. PubMed ID: 19043929
[TBL] [Abstract][Full Text] [Related]
16. Nevirapine resistance viral mutations after repeat use of nevirapine for prevention of perinatal HIV transmission.
Kuhn L; Sinkala M; Kankasa MP; Kasonde P; Thea DM; Aldrovandi GM
J Acquir Immune Defic Syndr; 2006 Jun; 42(2):260-2. PubMed ID: 16760802
[No Abstract] [Full Text] [Related]
17. Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants.
Moorthy A; Gupta A; Bhosale R; Tripathy S; Sastry J; Kulkarni S; Thakar M; Bharadwaj R; Kagal A; Bhore AV; Patil S; Kulkarni V; Venkataramani V; Balasubramaniam U; Suryavanshi N; Ziemniak C; Gupte N; Bollinger R; Persaud D
PLoS One; 2009; 4(1):e4096. PubMed ID: 19119321
[TBL] [Abstract][Full Text] [Related]
18. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012).
Eshleman SH; Mracna M; Guay LA; Deseyve M; Cunningham S; Mirochnick M; Musoke P; Fleming T; Glenn Fowler M; Mofenson LM; Mmiro F; Jackson JB
AIDS; 2001 Oct; 15(15):1951-7. PubMed ID: 11600822
[TBL] [Abstract][Full Text] [Related]
19. Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.
Bunupuradah T; Ananworanich J; Chetchotisakd P; Kantipong P; Jirajariyavej S; Sirivichayakul S; Munsakul W; Prasithsirikul W; Sungkanuparph S; Bowonwattanuwong C; Klinbuayaem V; Petoumenos K; Hirschel B; Bhakeecheep S; Ruxrungtham K
Antivir Ther; 2011; 16(7):1113-21. PubMed ID: 22024527
[TBL] [Abstract][Full Text] [Related]
20. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.
Delaugerre C; Rohban R; Simon A; Mouroux M; Tricot C; Agher R; Huraux JM; Katlama C; Calvez V
J Med Virol; 2001 Nov; 65(3):445-8. PubMed ID: 11596076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
